Dexamethasone decreases xenograft response to paclitaxel through inhibition of tumor cell apoptosis
The DOI matches its Crossref record.
Abstract
Glucocorticoid receptor (GR) activation has recently been implicated in the initiation of anti-apoptotic signaling pathways in epithelial cell lines grown in culture. However, the evidence that GR-mediated inhibition of tumor cell apoptosis is the mechanism that diminishes chemotherapy effectiveness in vivo is limited. We therefore initiated a breast cancer xenograft study to examine whether or not pretreatment with glucocorticoids (GCs) decreases tumor response to chemotherapy by inhibiting tumor cell apoptosis. Here we report a significant decrease in paclitaxel-induced apoptosis in xenografts from mice pretreated with dexamethasone (Dex). A significant difference in apoptosis in xenografts from Dex/paclitaxel versus paclitaxel treated animals was seen eight days following initiation of chemotherapy. Nine days later, mice treated with Dex/paclitaxel had significantly larger tumors compared with those that received paclitaxel alone (p = 0.032). Dex pretreatment did not significantly affect tumor cell proliferation rates. Taken together, these results demonstrate that systemic Dex administration results in significantly reduced breast cancer xenograft apoptosis in the context of chemotherapy treatment. We also found that systemic Dex treatment results in upregulation of the anti-apoptotic gene MKP-1 and downregulation of pro-apoptotic Bid and TRAIL genes in tumor cells six hours following Dex treatment. These in vivo gene expression changes correlated with significant inhibition of chemotherapy-induced apoptosis. Interestingly, the decreased chemotherapeutic response of Dex-pretreated tumors persisted for several weeks following treatment. These data suggest that GR-mediated transcriptional regulation of pro- and anti-apoptotic genes contributes to the mechanism through which GCs decrease paclitaxel-induced apoptosis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Glucocorticoids promote breast cancer metastasis
Obradović, M. M. S., Hamelin, B., Manevski, N., Couto, J. P., Sethi, A., Coissieux, M.-M., Münst, S., Okamoto, R., Kohler, H., Schmidt, A., et al. (2019) · Nature · doi:10.1038/s41586-019-1019-4 · Cited by 462
Cole, S. W. (2014) · PLoS Genetics · doi:10.1371/journal.pgen.1004601 · Cited by 415
“For example, socially isolated animals show glucocorticoid-related increases in breast cancer burden [46,47], and molecular analyses find glucocorticoid signaling to promote several cancer-related processes including mammary adipocyte metabolism [47,48], inhibition of tumor suppressor genes such as TP53 [49], and resi…”
BackgroundPan, D., Kocherginsky, M., & Conzen, S. D. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-0362 · Cited by 296
Self-citationHermes, G. L., Delgado, B., Tretiakova, M., Cavigelli, S. A., Krausz, T., Conzen, S. D., & McClintock, M. K. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0910753106 · Cited by 207
Self-citationSocial influences on clinical outcomes of patients with ovarian cancer
Lutgendorf, S. K., De Geest, K., Bender, D., Ahmed, A., Goodheart, M. J., Dahmoush, L., Zimmerman, M. B., Penedo, F. J., Lucci, J. A., Ganjei-Azar, P., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.39.4411 · Cited by 177
Metadata
- Authors
- Pang, D., & Kocherginsky, M.
- Venue
- Cancer Biology & Therapy
- Publisher
- Informa UK Limited
- Published
- 2006-08-01
- Volume
- 5
- Issue
- 8
- Pages
- 933-940
- ISSN
- 1538-4047 (ISSN-L)
- OpenAlex
- W2009672831
- Cited by
- 115
- References
- 0
- FWCI
- 2.83
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Dexamethasone decreases xenograft response to paclitaxel through inhibition of tumor cell apoptosis. https://app.cochat.ai/papers/10.4161/cbt.5.8.2875
- The paper
- Pang, D., & Kocherginsky, M. (2006). Dexamethasone decreases xenograft response to paclitaxel through inhibition of tumor cell apoptosis. Cancer Biology & Therapy. https://doi.org/10.4161/cbt.5.8.2875
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.